Author: Ken Dropiewski

Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors

BOSTON, July 19, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Allison Dorval, chief financial officer of Voyager Therapeutics, Inc. (“Voyager”), as a member […]

Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the […]

Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System

Investigational EVAS System Designed for Patients with Complex Abdominal Aortic Aneurysm IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a leader in the treatment of vascular disease, today announced the company’s ChEVAS™ (Chimney EndoVascular Aneurysm Sealing) System has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The ChEVAS […]

CORCYM Announces the First Patient Enrolled in MANTRA Study

MANTRA is the new CORCYM post-market clinical follow-up study in a real-world setting LONDON–(BUSINESS WIRE)–CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment of the first patient in the MANTRA study. MANTRA (Mitral, Aortic […]

New Study Demonstrates Retia Medical’s Multi-Beat Analysis (MBA™) Algorithm is More Accurate Than a Competing Cardiac Output Monitoring Technology in Cardiac Surgery

VALHALLA, N.Y., July 16, 2021 /PRNewswire/ — Retia Medical announced today the publication of a new study that further confirms the superior accuracy of its Multi-Beat Analysis (MBA™) algorithm in comparison to a competing option. The study, published on July 10th in BMC Anesthesiology (https://bmcanesthesiol.biomedcentral.com/track/pdf/10.1186/s12871-021-01415-5.pdf) compared the accuracy of two cardiac output monitors, the […]

Getinge Interim Report January-June 2021: Strong recovery in products for surgery

GETINGE, Sweden, July 16, 2021 /PRNewswire/ — “In total, sales increased by 3.6% organically compared with the second quarter 2020, and the order intake declined by 6.1% organically compared with 2020 when we received very large orders of advanced ICU ventilators”, says Mattias Perjos, President & CEO. “Cash flow remained strong and net debt […]

Canon Medical Partners with Cleerly to Tackle Heart Disease, the Leading Cause of Death

The collaboration breaks new ground by integrating Canon’s AI-powered CT technology with Cleerly’s digital pathway solution for analysis of coronary artery disease. TUSTIN, Calif.–(BUSINESS WIRE)–Canon Medical Systems, USA joins forces with Cleerly in a strategic partnership to support simple and streamlined adoption of cardiac CT and create a new standard […]

Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies […]

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

Amy Burroughs and Dr. Charles Semba Bring Extensive and Complementary Experience in Building Specialty Therapeutics Companies MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Company’s Board of […]